Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria.
Laia Curto-BarredoJ SpertinoI Figueras-NartV Expósito-SerranoA GuilabertG Melé-NinotX CubiróM Bonfill-OrtíJ Garcias-LadariaM VillarX García-NavarroI Bielsa-MarsolM VilavellaG AparicioC Baliu-PiquéA ÁlvarezN Lamas-DomenechX Duran-JordàE Serra-BaldrichA Giménez-ArnauPublished in: The British journal of dermatology (2018)